Related Experiment Video

Updated: Jun 18, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Is pretreatment with Beta-blockers beneficial in patients with acute coronary syndrome?

F Cuculi1, D Radovanovic, G Pedrazzini

  • 1Department of Cardiology, University Hospital Bern, Bern, Switzerland.

Cardiology
|November 13, 2009
PubMed

Insights

Beta-blocker therapy significantly reduces major adverse cardiac events in acute coronary syndromes (ACS). Starting beta-blockers in non-pretreated patients and continuing them in those already on therapy improves outcomes.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • The role of beta-blockers in acute coronary syndromes (ACS) is debated, with historical data from the thrombolysis era.
  • Optimal timing and continuation of beta-blocker therapy in contemporary ACS management require further investigation.

Purpose of the Study:

  • To evaluate the impact of pre-treatment and in-hospital continuation of beta-blockers on major adverse cardiac events (MACE) in patients with ACS.
  • To compare outcomes between patients pre-treated with beta-blockers, those initiated on therapy post-admission, and those never receiving beta-blockers.

Main Methods:

  • Analysis of 24,709 patients from the Acute Myocardial Infarction in Switzerland (AMIS Plus) registry.
  • Categorization into three groups: pre-treated and continued (A), initiated post-admission (B), and never received (C).
  • Comparison of MACE (re-infarction, stroke, in-hospital death) using multivariate analysis.

Main Results:

  • Group B patients were younger than groups A and C.
  • Multivariate analysis showed significantly reduced odds of MACE for both group A (OR 0.59, CI 0.47-0.74) and group B (OR 0.66, CI 0.55-0.83) compared to group C.
  • This indicates a protective effect of beta-blocker therapy regardless of pre-treatment status.

Conclusions:

  • Beta-blocker therapy demonstrates significant benefit in patients with ACS.
  • Initiating beta-blockers in non-pretreated ACS patients and continuing therapy in those with prior beta-blocker use is recommended.
  • These findings support the routine use of beta-blockers in ACS management.
Abstract

More Related Videos

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...